Rockwell Medical reported a 38% decline in net sales for Q2 2025, largely due to the transition of their largest customer to a new supplier, yet managed to maintain a positive cash flow from operations.
- Net sales for Q2 2025 decreased to $16.1 million, down from $25.8 million in Q2 2024.
- Over 80% of customers are secured under long-term contracts, providing stability amidst a challenging transition year.
- The company achieved adjusted EBITDA improvement, reducing losses from a negative $400,000 in Q1 to negative $200,000 in Q2 2025.
- New multiyear agreements with significant clients show potential for revenue recovery in the coming quarters.
- Guidance for 2025 remains unchanged with expected net sales between $65 million and $70 million.
Community Discussion